strong outlook hunter hall believes

Hunter Hall Global Value Limited
Monthly Performance Report for July

Says

Australian liver cancer treatment company Sirtex rose 34% over the month after delivering outstanding June quarterly results and 2009 financial year results. Product revenue rose 72% for the year to June 2009, to exceed $65.6m, with European and U.S sales growing 117% and 28% respectively. Operational cash flow rose to $20m, up 426% on the previous corresponding period, while net profit before tax surged 640%. With very pleasing momentum, a strong balance sheet, nil borrowings and rising cash flow, we believe Sirtex has a strong outlook.

http://www.aspectfinancial.com.au/docserver/00977442.pdf?fileid=00977442&datedir=20090814&edt=MjAwOS0wOC0xNCsxMToyNTo1MCsxMjArNjEwMDk1ODErZXRyYWRleG1sK3JlZGlyZWN0Ky9pbWFnZXNpZ25hbC9lcnJvcnBhZ2VzL0V0cmFkZVBERlRpbWVvdXQuaHRtbCsvaW1hZ2VzaWduYWwvZXJyb3JwYWdlcy9wZGZkZWxheWVkLmpzcA==&popup=true